BR
Closer to a Cure — 15 Years of Impact
£23.2m awarded to research since 2009; £18.2m directly to Centres of Excellence; Centres leveraged additional £23.2m — total £46.4m contribution to national investment
Key Metric 1
Blood test for high-grade brain tumours granted FDA Breakthrough Device Designation (2023); Barts Brain Tumour Centre grew from zero clinical trials in 2019 to running the most brain tumour clinical trials of any UK neuro-oncology centre in 2024